B. In the Claims

Please cancel claims 1 to 14 without prejudice and add claims 15 to 36.

Upon entry of the present amendment, the status of the claims will be as follows:

Claims 1-14 (canceled).

--15. (new) An antibody that specifically binds to a fragment of connective tissue growth factor (CTGF) polypeptide comprising the amino acid sequence of SEQ ID NO:4.

16. (new) The antibody of claim 15, wherein the fragment of CTGF comprises the amino acid sequence from residue 4 through 74 of SEQ ID NO:4.

17. (new) The antibody of claim 15, wherein the fragment of CTGF comprises the amino acid sequence from residue 75 through 172 of SEQ ID NO:4.

18. (new) The antibody of claim 15, wherein the fragment of CTGF comprises the amino acid sequence from residue 4 through 172 of SEQ ID NO:4.

19. (new) The antibody of claim 15, wherein the antibody is a monoclonal antibody.

20. (new) The antibody of claim 19, wherein the antibody is a human monoclonal antibody.

21. (new) The antibody of claim 15, wherein the antibody is a polyclonal antibody.

22. (new) The antibody of claim 15, wherein the antibody comprises murine antigen binding region residues and human antibody residues.

23. (new) A composition comprising the antibody of claim 15 and a pharmaceutically acceptable excipient or carrier.

24. (new) A method for treating a CTGF-associated disease or disorder comprising administering to a subject in need of the antibody of claim 15.

25. (new) The method of claim 24, wherein the disease or disorder is a fibroproliferative disease/disorder.

26. (new) The method of claim 24, wherein the disease or disorder is associated with proliferation of fibroblasts or vascular endothelial cells.

27. (new) The method of claim 24, wherein the disease or disorder is associated with angiogenesis or neovascularization.

28. (new) The method of claim 24, wherein the disease or disorder is cancer.

29. (new) The method of claim 28, wherein the cancer is selected from the group consisting of dermatofibromas, breast carcinoma desmosplasis, angiolipoma, and angioleiomyoma.

30. (new) The method of claim 28, wherein the cancer is associated with tumor growth or metastasis.

31. (new) The method of claim 25, wherein the fibroproliferative disease is selected from the group consisting of kidney fibrosis, scleroderma, pulmonary fibrosis, arthritis, hypertropic scarring, and atherosclerosis.

32. (new) An antisense molecule that binds to a nucleic acid sequence encoding a fragment of CTGF polypeptide comprising the amino acid sequence of SEQ ID NO:4.

33. (new) The antisense molecule of claim 32, wherein the fragment of CTGF comprises the amino acid sequence from residue 4 through 74 of SEQ ID NO:4.

34. (new) The antisense molecule of claim 32, wherein the fragment of CTGF comprises the amino acid sequence from residue 75 through 172 of SEQ ID NO:4.

35. (new) The antisense molecule of claim 32, wherein the fragment of CTGF comprises the amino acid sequence from residue 4 through 172 of SEQ ID NO:4.

36. (new) A method for treating a CTGF-associated disease or disorder comprising administering to a subject in need the antisense molecule of claim 32.--